Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Parabilis Medicines announced the appointment of Craig L. Tendler, M.D., an accomplished oncology drug development leader with over 30 years of experience and two decades at Johnson & Johnson, to its Board of Directors. Dr. Tendler will continue his role as scientific advisor while joining the board to support the company's advancement of zolucatetide across multiple indications and its broader pipeline of Helicon therapeutics.